All In MedTech

Device Trial Radar · NCT07632001

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

A Randomized Controlled Multicenter Trial, Examining the Effect of Miro3D Wound Matrix on the Rate of Complete Wound Closure of Chronic Diabetic Foot Ulcers

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Mar 2027

Study completion May 2027

Sponsor

Lead sponsor
Reprise Biomedical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate whether the Miro3D Wound Matrix, when used in addition to standard of care, improves healing outcomes in patients with chronic diabetic foot ulcers. Diabetic foot ulcers are a common and serious complication of diabetes and may be difficult to heal despite appropriate treatment. Standard of care typically includes regular wound cleaning, debridement (removal of dead tissue), offloading (reducing pressure on the wound), and moisture-balancing dressings. However, some wounds fail to heal with standard treatment alone. Miro3D Wound Matrix is a three-dimensional, acellular scaffold derived from porcine tissue that is intended to support wound healing. This study will compare outcomes in patients treated with Miro3D plus standard of care versus standard of care alone. Approximately 180 adult subjects with non-healing diabetic foot ulcers will be enrolled at multiple clinical sites in the United States. After a two-week screening period, eligible participants will be randomly assigned to receive either Miro3D in addition to standard of care or standard of care alone. Subjects will be followed for up to 12 weeks with weekly clinic visits. The primary objective of the study is to determine whether treatment with Miro3D increases the rate of complete wound closure and improves reduction in wound size compared to standard of care alone. Safety will also be evaluated by monitoring adverse events throughout the study.

Conditions

  • Diabetic Foot Ulcers (DFUs)
  • Diabetic Foot
  • Chronic Wounds

Interventions

  • Miro3D Wound MatrixDevice

    Miro3D Wound Matrix is a sterile, acellular, three-dimensional scaffold derived from porcine liver tissue and applied topically to the wound following appropriate wound bed preparation to support tissue regeneration and healing.

  • Standard of CareOther

    Standard of care includes sharp debridement, offloading using a protocol-defined device, and appropriate moisture-retentive dressings.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving Complete Wound Closure of the Target Diabetic Foot Ulcer at 12 WeeksTime frame: Up to 12 weeks
  2. Mean Percentage Reduction in Target Ulcer Surface Area From Baseline to 12 WeeksTime frame: Baseline through 12 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Foot Care

    Phoenix, Arizona · Recruiting

  • West Boca Center for Wound Healing

    Coconut Creek, Florida · Not yet recruiting

  • Solutions Medical Research

    Coral Gables, Florida · Recruiting

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.